Enveric Biosciences
ENVB
26 hedge funds and large institutions have $3.61M invested in Enveric Biosciences in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
680% more call options, than puts
Call options by funds: $78K | Put options by funds: $10K
0% more funds holding
Funds holding: 26 → 26 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
19% less capital invested
Capital invested by funds: $4.45M → $3.61M (-$831K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.35M |
| 2 |
Renaissance Technologies
New York
|
+$702K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$305K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$79.5K |
| 5 |
VF
Virtu Financial
New York
|
+$66.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$690K |
| 2 |
Goldman Sachs
New York
|
-$55K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$53K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$48.6K |
| 5 |
Two Sigma Investments
New York
|
-$39K |
ENVB Hedge Fund Activity: Q1 2022 in Review
26 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2022, worth a combined $3.61M — down 19% from $4.45M a quarter earlier.
Fund positioning in ENVB was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $2.35M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $690K sold.
- 26 institutional investors held Enveric Biosciences (ENVB) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $3.61M of Enveric Biosciences stock for Q1 2022, down 19% quarter-over-quarter.
- 5 funds opened new Enveric Biosciences positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest Enveric Biosciences buyer in Q1 2022 was Hudson Bay Capital Management, an estimated $2.35M added.
- The largest Enveric Biosciences seller in Q1 2022 was Pura Vida Investments, an estimated $690K sold.
Based on aggregated 13F filings for Q1 2022.